Tempest Therapeutics Inc
Company Profile
Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USAT: +1 415 798-8589
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Are ASX REITs the better way to own property?
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,279.00 | 3.00 | -0.03% |
| CAC 40 | 8,630.84 | 5.95 | -0.07% |
| DAX 40 | 26,459.36 | 19.05 | 0.07% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,768.28 | 18.17 | 0.17% |
| HKSE | 25,453.23 | 336.38 | 1.34% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 69,220.25 | 506.45 | 0.74% |
| NZX 50 Index | 13,721.98 | 132.40 | -0.96% |
| S&P 500 | 7,785.76 | 13.23 | -0.17% |
| S&P/ASX 200 | 9,073.20 | 6.10 | -0.07% |
| SSE Composite Index | 3,982.65 | 55.48 | 1.41% |